Table 2.
Clinicopathological information of samples included in synovial sarcoma tissue microarray and used for further analyses.
| Total | Percentage | |
|---|---|---|
| Number of patients | 78 | |
| Number of samples | 91 | |
| Number of samples/patient | ||
| 1 sample | 66/78 | 85 % |
| 2 samples | 11/78 | 14 % |
| 3 samples | 1/78 | 1 % |
| Clinical information of patients | ||
| Gender | ||
| Male | 42/78 | 54 % |
| Female | 36/78 | 46 % |
| Median age at diagnosis in years with range | 36 years (12–85 years) | |
| Development of disease recurrence (metastasis/local relapse) | 49/78 | 63 % |
| Outcome | ||
| Death of disease | 37/78 | 47 % |
| No evidence of disease | 34/78 | 44 % |
| Alive with disease | 3/78 | 4 % |
| Lost to follow-up | 4/78 | 5 % |
| Median overall survival in months with range | 75.5 months (7–452 months) | |
| Clinicopathological information of the samples | ||
| Presence of the translocation was confirmed with | ||
| FISH | 39/91 | 43 % |
| Karyotyping | 34/91 | 37 % |
| RT-PCR | 11/91 | 12 % |
| IHC, positivity for SS18-SSX staining | 7/91 | 8 % |
| Origin of sample | ||
| Primary tumor | 58/91 | 64 % |
| Metastasis | 21/91 | 23 % |
| Local recurrence | 12/91 | 13 % |
| Grading (FNCLCC) – only including primary tumors | ||
| Grade 3 | 21/58 | 36 % |
| Grade 2 | 15/58 | 26 % |
| Not specified | 15/58 | 26 % |
| Not applicable because of neoadjuvant therapy | 7/58 | 12 % |
| Morphology – only including primary tumors | ||
| Monophasic | 25/58 | 43 % |
| Biphasic | 16/58 | 28 % |
| Not specified | 17/58 | 29 % |
| Median tumor size– only including primary tumors (range) | 5.9 cm (0.5–28.5 cm) | |
| Localization of sample | ||
| Lower extremities | 42/91 | 46 % |
| Thoracic region | 29/91 | 32 % |
| Upper extremities | 9/91 | 10 % |
| Abdominal region | 6/91 | 7 % |
| Vertebrae | 4/91 | 4 % |
| Brain | 1/91 | 1 % |
| Pre-treatment of sample | ||
| Treatment-naive | 65/91 | 72 % |
| Systemic therapy alone | 21/91 | 23 % |
| Isolated limb perfusion | 2/91 | 2 % |
| Systemic therapy+ radiotherapy on site of sampling | 2/91 | 2 % |
| Radiotherapy on site of sampling | 1/91 | 1 % |
Abbreviations: FISH: fluorescence in situ hybridization RT-PCR: reverse transcription polymerase chain reaction, IHC: immunohistochemistry, FNCLCC: Fédération Nationale des Centres de Lutte Contre le Cancer.